bioAffinity Technologies, Inc. 8-K

What Happened
On March 17, 2026, bioAffinity Technologies, Inc. (BIAF) filed a Form 8‑K (Item 8.01) to report that it issued a press release announcing the release of a new clinical case study. The study highlights the benefit of adding CyPath® Lung — a noninvasive test for lung cancer — to the diagnostic pathway for a high‑risk patient who presented with multiple pulmonary nodules. The press release is attached to the filing as Exhibit 99.1.

Key Details

• Filing date: March 17, 2026 (Form 8‑K, Item 8.01).
• Subject: release of a clinical case study emphasizing CyPath® Lung use in a high‑risk patient with multiple pulmonary nodules.
• Product: CyPath® Lung — described as a noninvasive lung cancer diagnostic test.
• Exhibit: Press release filed as Exhibit 99.1 (also referenced in Item 9.01 exhibits list).

Why It Matters
This disclosure is a company update about clinical evidence and marketing communications rather than financial results or leadership changes. For investors, such case studies can support product credibility, clinician awareness, and potential commercial adoption of CyPath® Lung, which could affect future revenue opportunities if uptake increases. The filing does not present new financial statements or quantified commercial impact — it documents the public release of the case study information.